Zika-Specific Immune Response
2
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Vrczkadna08500vp
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 2 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults
Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults
Research Network
Common Treatments
- Vrczkadna08500vp1
- Vrczkadna09000vp1
Active Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)2
Top Investigators
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
Related Conditions
- Prevention Of Zika Infection2